Oculis’s OCS-01 Sparkles Treating Front-Of-Eye Inflammation
Swiss Biotech To Now Talk With FDA On Two Phase III Designs
Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.
